novaMETABOLISM Combo

PROBIOTIC COMBINATION FOR THE MANAGEMENT OF PRE-DIABETES CONDITION & METABOLIC SYNDROME

B. psychraerophilum Q5 (DSM 33131) L. hordei KLL19 (DSM 33127)
L. harbinensis G8 (DSM 33126)

Recommended dosage: 7 billion cells per day

Scientifica Data

Probiotics were investigated in an in vitro diabetic model, with regard to hyperglycemia, insulin resistance, hypercholesterolemia and dyslipidemias. In particular, the following were analyzed:

• analysis of cytotoxicity and production of reactive oxygen species;
• quantification of glucose and insulin to analyze insulin resistance;
• the main markers involved in glucose metabolism (such as AKT, GLUT4 and PGC-1). To better understand the effect, after the first screening the most effective combinations were studied in a complete metabolic model, including the intestinal passage up to the metabolic effect on the liver:
• evaluation of liver damage;
• analysis of free cholesterol levels;
• lipids accumulation and circulating LDL;
• cholesterol biosynthesis and metabolism (AMPK, PCSK9, SREBP2 and LDLr);
• hepatic metabolism, focusing on the main isoforms of CYP450;
• inflammatory picture and pro-inflammatory cytokines analysis

Results

The combination of the three next generation probiotics showed an amplified positive effect (p<0.05) on intestinal and hepatic metabolism. Remarkably, the combo resulted to significantly (p<0.05 vs control) reduce the lipid accumulation. Contact us to receive more information. Here it is reported the global effect of probiotics combination on the in vitro diabetic model:

PROBIOTICS COMBO EFFECT VARIATION VS REFERENCE